1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Jeisys Medical Inc.

Jeisys Medical Inc.

287410.KQ
Jeisys Medical Inc.KR flagKOSDAQ
12,900.00
KRW
+20.00
- -
974.74BMarket Cap
Jeisys Medical Inc.
287410.KQ
(KOSDAQ)

Recent

price

12,900.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
- -
- -
875.08
1,166.36
1,636.78
1,891.65
2,200.85
Revenue per Share
-8
-1.26
9
138
195
381
328
366.79
Basic EPS, GAAP
-8.96
-21.63
12.06
240.52
251.32
164.86
233.57
140.31
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
93.81
134.6
103.05
-64.84
200.79
577.54
878.74
- -
Book Value per Share
1,144.22
2,492.37
1,750.56
294.85
669.78
1,098.87
1,247.77
1,480.46
Tangible Book Value per Share
1
3
4
55
70
71
76
76
Basic Weighted Avg Shares
- -
- -
- -
47,829
81,296
116,550
143,030
167,823
Sales/Revenue/Turnover
- -
- -
- -
23.06
29.04
29.2
25.39
35.41
Operating Margin (%)
- -
- -
- -
2,329
2,474
3,041
4,263
3,387
Depreciation Expense
-6
-4
40
7,543
13,592
27,130
24,800
27,969
Net Income, GAAP
- -
- -
15.2
12.95
- -
20.29
29.27
25.72
Effective Tax Rate (%)
- -
- -
- -
15.77
16.72
23.28
17.34
16.67
Profit Margin (%)
1,392
8,251
8,319
15,346
30,146
47,900
66,991
64,250
Working Capital
539
563
587
8,125
1,729
11,315
22,271
- -
LT Debt
826
7,663
7,703
16,959
47,654
79,955
96,250
112,891
Total Equity
- -
- -
-0.55
50.89
- -
33.23
22.86
38.91
Return on Invested Capital (%)
- -
- -
5.98
167.11
- -
64.97
32.6
76.41
Return on Capital (%)
- -
-1.6
9.13
- -
- -
98.44
46.11
102.61
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
3,336
43,238
- -
LT Borrowings
21,083
20,974
- -
LT Finance Leases
1,188
985
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
75
75
75
Market Capitalization
787,528
606,845
981,389

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
90,510
142,713
128,604
Cash, Cash Equivalents & STI
48,830
96,583
- -
Accounts Receivable, Net
14,042
17,407
- -
Inventories
22,617
24,060
- -
Total Current Liabilities
23,519
67,191
64,355
Payables & Accruals
- -
- -
- -
ST Debt
3,336
43,238
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
77.97%
20.38%
Free Cash Flow
- -
4,907.03%
50.44%
Net Income, GAAP
- -
3,598.38%
-8.59%
Sales/Revenue/Turnover
- -
- -
22.72%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
25,334
30,770
28,642
31,803
116,550
2023
29,105
35,161
39,107
39,657
143,030
2024
43,956
45,104
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
92
104
101
- -
381
2023
92
81.41
104.05
- -
328
2024
91
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Holdco Nuvo Group D.G Ltd. Ordinary Shares (NUVO)
Vascular Solutions LLC (VASC)
GBS Inc. (GBS)
Inogen, Inc. (INGN)
Shanghai General Healthy Information and Technology Co., Ltd. (605186.SS)
EOFLOW Co.,Ltd. (294090.KQ)
Business
Jeisys Medical Inc. (287410.KQ) designs, develops, manufactures and markets energy-based medical aesthetic devices for plastic surgeons, dermatologists, physicians and healthcare professionals worldwide; core products include radiofrequency (RF) and high-intensity focused ultrasound (HIFU) systems such as DENSITY with its Alpha Tip for monopolar/bipolar skin remodeling, LinearZ for lifting and tightening, ULTRAcel Q+ for skin rejuvenation, lifting/tightening, pigmentation, fat reduction, acne, tattoo removal and scars/striae under ULTRAcel branding, Cellec V, LIPOcel, POTENZA, AcGen, TRI-BEAM Premium picosecond laser, Edge ONE, SmoothCool IPL and INTRAcel fractional RF microneedle systems; the company distributes through global networks including subsidiaries and partners targeting Asia-Pacific, North America, Europe and emerging markets like India and Vietnam. Founded in 2001 and headquartered in Seoul, South Korea, Jeisys operates internationally with branches in Japan, Australia, Vietnam and the newly established JEISYS MEDICAL NORTH AMERICA INC. in 2025 to drive U.S. market penetration; it serves aesthetic dermatology, cosmetology and plastic surgery segments with FDA, CE, PMDA and other regulatory approvals. Recent developments encompass the 2023 launch of DENSITY RF platform and 2025 introduction of its Alpha Tip alongside Jeisys Institute of Aesthetic Medicine (JIAM) education hub debuted at Jeisys TEA Seoul 2025; LinearZ launched in 2022; full privatization via Archimed-backed Syracuse Subco Inc. acquisition of 100% stake completed October 2024 with delisting from KOSDAQ; U.S. subsidiary launch at ASLMS 2025 featuring DENSITY, LinearZ and SmoothCool; India DENSITY rollout May 2025; new CEO Rami Lee appointment in 2024; and export awards including $70 million milestone in 2023.